Exploring the impact of silymarin on the risk of cataract in patients with chronic hepatic diseases

• Main Authors: Jih-Rong Yang, 楊季蓉
• Other Authors: 廖嘉鴻
• Format: Others
• Language: zh-TW
• Published: 2014
• Online Access: http://ndltd.ncl.edu.tw/handle/f66neg

碩士 === 臺北醫學大學 === 藥學系(碩博士班) === 102 === Background:Reduced levels of glutathione in patients with chronic liver disease lead to oxidative stress in crystalline lens proteins.Because few past retrospective cohort studies exist,the purpose of this study was to investigate the effects of silymarin on the risk of cataract development in patients who have chronic liver disease. Method:Patients who were diagnosed with chronic liver disease between 2000 and 2011 were selected from the National Health Insurance Research Database(year 2000);the patients were then sex- and age-matched(1:2 ratio)with randomly selected patients who did not have chronic liver disease.The risk of developing cataracts was estimated by Cox proportional hazards model(95% confidence interval). Results:The hazard ratio for cataract development in the group that received silymarin was 0.83, and the maximum decrease was observed for cumulative doses exceeding 1461 DDD(p<0.001).The mean time of cataract onset was 2534±662 days.The hazard ratio for the group that did not receive silymarin was 26.89. Conclusion:Silymarin can reduce the incidence of cataracts in patients with chronic liver disease who have a higher risk of developing cataracts.